Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Thursday, 30 March 2017

New Artificial Intelligence Research Institute Launched in Toronto to Anchor Canada as a Global Economic Supercluster

 
New Artificial Intelligence Research Institute Launched in Toronto to Anchor Canada as a Global Economic Supercluster
Vector Institute Aims to Produce World's Largest Number of Deep Learning AI Graduates TORONTO, March 30, 2017 /PRNewswire/ -- Vector Institute, a new independent research facility for artificial intelligence (AI), opened its doors at the MaRS Discovery District in downtown Toronto...
Read more

Inauguration d'un nouvel institut de recherche en intelligence artificielle à Toronto qui établira le Canada à titre de super regroupement de l'économie mondiale
L'Institut Vecteur a pour objectif de former le plus grand nombre de diplômés en IA liée à l'apprentissage profond au monde TORONTO, le 30 mars 2017 /PRNewswire/ -- L'Institut Vecteur, un nouvel établissement de recherche indépendant pour l'intelligence artificielle (IA), a ouvert ses...
Read more

Tenda brilló en CeBIT 2017
HANNOVER, Alemania, 30 de marzo de 2017 /PRNewswire/ -- CeBIT de este año estuvo en gran parte dedicado a la red y soluciones móviles y tuvo lugar del 20 al 24 de marzo. Tenda, uno de los principales fabricantes de equipos de red, participó en este evento con toda la serie de productos...
Read more

Guangzhou verschickt Einladungen zum Fortune Global Forum im Rahmen der Jahreskonferenz Boao Forum for Asia
GUANGZHOU, China, 30. März 2017 /PRNewswire/ -- Im Rahmen des Boao Forum for Asia, einer jährlich stattfindenden Wirtschaftskonferenz, wird die Delegation der Stadtverwaltung von Guangzhou das Symposium des Fortune Global Forum veranstalten. Guangzhou verschickt zu diesem Zweck derzeit...
Read more

David Marquette, Jez Humble, Denise Jacobs to Keynote AGILE2017 Conference
Largest international gathering of Agilists to be held August 7 - 11 in Orlando, Florida PORTLAND, Oregon, March 30, 2017 /PRNewswire/ -- Agile Alliance today announced the keynote speakers for AGILE2017, the largest annual global gathering of Agile practitioners. The conference is...
Read more

DoubleVerify Reports a Record Number of Brand Ads Effectively Blocked from Inflammatory and Unsafe Content Online
Inflammatory and fake news violations more than double since January NEW YORK, March 30, 2017 /PRNewswire/ -- New data from DoubleVerify, the recognized leader in digital quality solutions, reports that a record number of brand ads were successfully blocked from appearing adjacent to...
Read more

Airborne Wireless Network Files for FCC Experimental License for System Demonstration
Marking Significant Progress in the Commercialization of Company's Patented Infinitus Super Highway™ SIMI VALLEY, California, March 30, 2017 /PRNewswire/ -- Airborne Wireless Network (OTCQB: ABWN) has filed for an experimental Federal Communication Commission license file number...
Read more

EU Commission: EIB teams up with KB to battle youth unemployment, climate change

EIB teams up with KB to battle youth unemployment, climate change

The EIB is lending EUR 100m to Komerční Banka for projects implemented by small and medium-sized businesses supporting youth employment and climate action.  

Read more

Letter by President Dijsselbloem to President Tajani concerning the plenary statement by the President of the Eurogroup as regards the second review of the economic adjustment programme for Greece

Subject: Plenary statement by the President of the Eurogroup - state of play of the second review of the economic adjustment programme for Greece

Dear Mr Tajani,

Thank you for your letter of 29 March 2017 inviting me to the Plenary Session of 4 April 2017. We have had different correspondences on the matter before. As indicated before I am willing to address the European Parliament on Greece. Let me add in this respect that I informed the Parliament on the state of play of the economic adjustment programme for Greece only last week, on 21 March, in my regular exchange of views with the ECON Committee.

Unfortunately, as indicated by my services already last week, I am no longer available on that date.

I would like to assure you that I remain committed to continue the discussion on this issue with the European Parliament. I would therefore be available to participate in a future plenary debate. I hope we can find a suitable moment together. In order to have a good debate, I would like to suggest to have the meeting after completion of the second review.

Yours sincerely, 

Jeroen Dijsselbloem

Read more

Speech by President Donald Tusk at the EPP Malta congress 2017

Dear friends, I am sure that by now you've had enough of speeches, so let me share just one reflection but, in my opinion, a key one.

Five days ago in Rome, right before signing the Rome Declaration, I said, "Europe as a political entity will either be united, or will not be at all. Only a united Europe can be a sovereign Europe in relation to the rest of the world. And only a sovereign Europe guarantees independence for its nations, guarantees freedom for its citizens. The unity of Europe is not a bureaucratic model. It is a set of common values and democratic standards. Today it is not enough to call for unity and to protest against multiple speeds. It is much more important that we all respect our common rules such as human rights and civil liberties, freedom of speech and freedom of assembly, checks and balances, and the rule of law. This is the true foundation of our unity".

And yesterday, right after receiving the letter from Prime Minister Theresa May, invoking Article 50, I said that "paradoxically, there is also something positive in Brexit. Brexit has made us, the community of 27, more determined and more united than before. I am fully confident of this, especially after the Rome Declaration, and I can say that we will remain determined and united also in the future, also during the difficult negotiations ahead.

Those two statements are connected by one thought, by one conviction: that the key to our future is in the unity and sovereignty of Europe. In recent years, Europeans - from Warsaw to London, from Athens to Helsinki - have been made to believe that an integrating Europe is a threat to national and state sovereignty.

That the European Union, that Brussels, are demanding a reduction of patriotism. That, as we integrate within the EU, we must sacrifice our sovereignty. That we are losing control over our own fate, as we delegate part of our powers to the European Community. That by strengthening this community, we inevitably weaken the national one. That it's becoming more and more difficult to reconcile being Europeans and patriots. This was in fact the main theme of anti-EU campaigns in the UK, and in many other places. Virtually in the whole of Europe.

This is a view which is both foolish and dangerous. Our mission should be to make Europeans realise that it's exactly the opposite. That a strong EU, capable of being sovereign in relation to the external world, capable of protecting its catalogue of values and culture, capable of protecting its external border, is the best, and perhaps the only guarantee of national and state sovereignty. Today's world has swept away the illusion that everyone wants to emulate European cultural and political standards. The migration crisis, Russian aggression in Ukraine, events in Turkey, Brexit and many other events show that proclaiming the "end of history", proclaiming the ultimate triumph of liberal democracy, peace and international order, have turned out to be - to put it mildly - exaggerated. For rational and responsible patriots who want to maintain sovereignty and independence of their nations and states, there is no alternative to a united and sovereign Europe.

We must challenge the populists. We must say loud and clear that nationalisms and separatisms which try to weaken the EU are the opposite of modern patriotism. Those who take aim at European unity, threaten also their own communities, weakening their own state sovereignty.

Words such as security, sovereignty, dignity and pride must return to our political dictionary. There is no reason why, in public debate, extremists and populists should have a monopoly on these terms. Today they are efficiently and cynically taking advantage of social fears and uncertainty, building their own model of security on prejudice, authoritarianism and organised hatred. Our response must be clear and decisive.

Firstly, there is no contradiction between liberal democracy and the need for order and security. Only free and law-abiding societies can truly be safe.

Secondly, there is no contradiction between a Europe which is integrated and sovereign in relation to the external world, and the independence of our nations and countries. Quite the opposite: the more Europe is united, the more it is sovereign, and therefore capable of protecting sovereign nations.

Thirdly, moderation, common sense and political rationalism do not stand in contradiction to force, courage and determination. People want authority which is wise, moral and strong all at the same time. And this is the right role for the EPP. This is your role. Thank you.

Read more

Article - Timeline: Parliament's continued support for Ukraine

Plenary sessions : A visa-free regime for Ukrainians travelling to the EU is just the latest step in the European Parliament's continued support of Ukraine. The Parliament has consistently shown solidarity by condemning Russia's military involvement and illegal annexation of Crimea and promoting political and economic reforms.

Source : © European Union, 2017 - EP

Read more

Statement by the Spokesperson on the recent developments in Venezuela

The recent rulings of the Supreme Court of Venezuela are calling into question the constitutional powers of the National Assembly and restricting the parliamentary immunity of its members, who were democratically elected by the people of Venezuela.

Read more

DBV Technologies, BioNet-Asia and Geneva University Hospitals Announce Phase I Trial Results of Viaskin rPT in Pertussis Booster Vaccination

DBV Technologies    

Published: 22:30 CEST 30-03-2017 /GlobeNewswire /Source: DBV Technologies / : DBV /ISIN: FR0010417345


  

 

 

DBV Technologies, BioNet-Asia and Geneva University Hospitals Announce Phase I Trial Results of Viaskin rPT in Pertussis Booster Vaccination

 

 

 

PARIS, BANGKOK and GENEVA March 30, 2017 - DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), the Geneva University Hospitals (HUG) and BioNet-Asia Co. Ltd today announced results from a Phase I trial assessing Viaskin rPT's ability to boost immunity against pertussis by epicutaneously administering two doses of BioNet's recombinant pertussis toxin.

 

The study evaluated the safety and immunogenicity of Viaskin rPT 25 mcg (n=25) and 50 mcg (n=25) in 60 healthy adults randomized 5:1 to each dose cohort versus placebo (n=10). The primary endpoint of the study was the incidence of treatment-emergent adverse events (AEs) related to the application of Viaskin rPT, and secondary objectives assessed humoral responses compared to placebo. After further analysis of the data, limitations in the study design and protocol were observed. DBV, HUG and BioNet continue to review preliminary study data, and are evaluating if further development pathways, including optimization of Viaskin rPT, will be explored.

 

Mild application-site reactions were observed in all cohorts, and no serious adverse events (SAEs) attributed to study drug were reported. After the second application of Viaskin rPT 25 mcg and 50 mcg, measures of PT-specific antibody responses by enzyme-linked immunosorbent assay (ELISA) were not observed to be statistically significant, but serum samples showed a wide distribution of human anti-PT IgG antibodies. In the placebo, Viaskin rPT 25 mcg and 50 mcg cohorts, respectively, 30% (n=3), 36% (n=9) and 40% (n=10) of subjects were seropositive at baseline, defined in this study as having anti-PT IgG antibodies greater than or equal to 5 UL/mL, and thus not assessable for seropositivity analysis. In the seronegative population at baseline, two subjects on Viaskin rPT 50 mcg (13.3%), one subject on Viaskin rPT 25 mcg (6.3%) and no subjects on placebo (0.0%) were seropositive following the second administration of Viaskin rPT. DBV, HUG and BioNet continue to evaluate the immunogenicity findings observed to better understand potential future development plans for Viaskin rPT.

 

"We have seen promising preclinical data showing significant immunogenicity with Viaskin rPT. We can now take key learnings from this first clinical trial attempt, and implement the necessary improvements needed to potentially conduct more informative studies and improve the immunogenicity of Viaskin rPT in the future," said Professor Claire-Anne Siegrist, Director of the Center of Vaccinology of HUG. "The application of the novel Viaskin technology platform in immunization enables us to explore potential areas of development for patients that are currently being underserved by approved vaccines today."

 

This Phase I proof of concept study was conducted under the supervision of Professor Claire-Anne Siegrist from the Clinical Research Center of HUG and was sponsored by DBV Technologies.

 

About the Phase I Viaskin rPT Trial

This Phase I dose-escalation, randomized, double-blind, placebo-controlled safety and immunogenicity study assessed the safety of BioNet's genetically-detoxified recombinant pertussis toxin administered by DBV's Viaskin patches in 60 young healthy adults. Secondary endpoints assessed the subjects' humoral responses elicited by Viaskin rPT 25 mcg and 50 mcg compared to placebo. Immune cellular responses were also monitored as exploratory endpoints.

 

The trial was conducted in the Clinical Research Center of the Geneva University Hospitals. Men and women aged 18 to 40 years who were vaccinated during childhood against pertussis were randomized into two cohorts of 30 subjects each. The Viaskin patches were applied for 48 hours, with a two-week interval between applications. Four weeks after the second Viaskin application, participants received one dose of Boostrix® dTpa vaccine to ensure the recall of immunity against diphtheria, tetanus and the three pertussis antigens (only a single antigen will be delivered through Viaskin rPT). All subjects were observed after each application. Local and systemic adverse events were monitored. 

 

The first cohort received two applications of Viaskin rPT 25 mcg or placebo. Following a positive DSMB review, the second patient cohort received two applications of Viaskin rPT 50 mcg or placebo.

 

About Bordetella Pertussis

Pertussis, commonly known as whooping cough, is a highly contagious respiratory illness caused by a type of bacteria known as Bordetella pertussis. Pertussis vaccination is recommended as part of routine childhood immunization. Although the incidence of pertussis has declined as a result of immunization of infants and young children, vaccine-induced immunity does not persist for long.  This phenomenon, known as waning immunity, has increased since the introduction of acellular pertussis vaccines in 1996, which tend to provide short-lived protection against the Bordetella pertussis bacteria. According to the U.S. Centers for Disease Control and Prevention (CDC), there are 16 million pertussis cases worldwide each year, mainly in adolescents and adults who often can infect infants who have not yet completed their pertussis immunization. In these young patients, pertussis can be severe and fatal.

Booster immunizations are now recommended for adolescents and adults, but compliance is not always high. A new vaccine technology that is patient-friendly, painless and non-invasive could help increase the compliance for booster immunization against whooping cough.

 

About DBV Technologies 

DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.

DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

 

About Geneva University Hospitals

The Geneva University Hospitals (HUG), reference academic institution at both national and international level, gather eight public hospitals of Geneva. Their centres of excellence cover hepato-biliary and pancreatic diseases, cardiovascular diseases, oncology, musculoskeletal and sports medicine, old age medicine, genetic medicine and vaccinology. Its Center of Vaccinology, led by Professor Claire-Anne Siegrist, gained international recognition through the performance of a large first-in-humans Phase I randomized clinical trial that enrolled 115 subjects to characterize the safety and immunogenicity of the VSV-ZEBOV Ebola vaccine candidate.

 

With their 10,500 employees, the HUG welcome each year 60,000 hospitalized patients and assure 91,000 emergencies, 990,000 consultations or ambulatory care and 26,000 surgical procedures. More than 800 physicians, 3,000 interns and 150 apprentices perform their training here. The HUG are working closely with the Faculty of Medicine of the University of Geneva and WHO in various training and research projects. They develop partnerships with CHUV, EPFL, CERN and other actors from the Lemanic Health Valley. More information on: www.hug-ge.ch

 

About BioNet-Asia

BioNet-Asia offers access to vaccine and technology through biotech innovation and partnering networks. BioNet has built several international partnerships fostering vaccine self-reliance and leading to the supply of billions of doses of vaccines worldwide. BioNet has also a broad pipeline of vaccines in R&D and clinical stages. In December 2016 BioNet received Marketing Authorization Approval from the Thai Food and Drug Administration for its standalone recombinant acellular Pertussis (aP) vaccine Pertagen(TM) and Tetanus-diphtheria-acellular Pertussis (TdaP) combination vaccine Boostagen(TM). BioNet's new generation pertussis vaccines are produced from a proprietary Bordetella pertussis strain expressing genetically-inactivated Pertussis Toxin (PTgen). The unique properties of PTgen enables the vaccines to induce superior anti-PT immune response as demonstrated in comparative studies. Both BioNet recombinant aP and TdaP vaccines are indicated for booster use in adolescents and adults. For additional information, please visit www.bionet-asia.com  

 

Forward Looking Statements

This press release may contain forward-looking statements and estimates, including statements regarding the potential safety and efficacy of Viaskin rPT and statements reflecting management's expectations for clinical development of Viaskin rPT. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, the products of the Company have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical preclinical results may not be predictive of future clinical trial results, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French Autorité des Marchés Financiers, the Company's Securities and Exchange Commission filings and reports, including in the Company's Annual Report on Form 20-F for the year ended December 31, 2016 and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.

 

DBV Technologies Contact

Susanna Mesa

Senior Vice President, Strategy
+1 212-271-0861
susanna.mesa@dbv-technologies.com

 

Media Contact

Andrea Fassacesia, Weber Shandwick
+1 212-445-8144
afassacesia@webershandwick.com

 

Media Contact Europe

Caroline Carmagnol, Alize RP, Relations Presse

+33 (0)6 64 18 99 59 

caroline@alizerp.com

 

HUG Media Contact

Nicolas de Saussure, PR Officer

 +41 (22) 372 60 06

 nicolas.desaussure@hcuge.ch

 

BioNet Contact

Laurent Dapremont, Director Strategic Business Development, BioNet-Asia Co. Ltd.

+66 (2) 361 8110

laurent.d@bionet-asia.com  



PDF Version



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: DBV Technologies, Green Square - Bâtiment D 80/84 rue des Meuniers, Bagneux FR-92220, France
If you would like to unsubscribe and stop receiving these e-mails click here.

Ericsson 600 MHZ products ready in Q3 2017

Ericsson North America    

Ericsson 600 MHZ products ready in Q3 2017

  • The FCC has provisionally awarded assignments of 600 MHz spectrum to winning bidders
  • Ericsson's 600 MHz solutions enable operators to meet their aggressive timelines for commercial deployment in the repurposed spectrum
  • Operators can extend and enhance coverage by using these low-band frequencies

Ericsson's (NASDAQ:ERIC) 600 MHz suite of products will be ready for commercial deployment by Q3 2017, providing operators the ability to quickly launch services in their new 600 MHz spectrum holdings.

The news follows the FCC's completion of the final phase of its incentive auction, which repurposed spectrum for wireless broadband services. As a result, operators will receive access to spectrum to provide service in the 600 MHz band.  

The new 600 MHz low-band spectrum allows operators to extend and enhance coverage by utilizing low band radio wave propagation. For example, in rural areas more coverage can be provided per cell site, which drastically improves economics. This enables a more competitive and ultimately a better choice of wireless service for customers.

Glenn Laxdal, Head of Network Products, Ericsson North America, says: "The FCC's first-of-its-kind Incentive Auction provides guidance to other countries wishing to repurpose spectrum. The quick deployment of service in the 600 MHz spectrum will help improve the coverage footprint, increase data speeds and enable continued industry growth."

Ericsson's 600 MHz products maximize low-band spectral efficiency through advanced MIMO capabilities. The 600 MHz products are based on Ericsson's 4478 radio platform, which was introduced at the recent Mobile World Congress.

Ericsson is present today in all high traffic LTE markets including US, Japan, and South Korea, and is ranked first for handling the most global LTE traffic.  More than 270 LTE RAN and Evolved Packet Core networks have been delivered by Ericsson worldwide, of which more than 200 are live commercially.

 

Glenn Laxdal

 

NOTES TO EDITORS

For media kits, backgrounders and high-
resolution photos, please visit
www.ericsson.com/press

FOLLOW US:

www.twitter.com/ericsson
www.facebook.com/ericsson
www.linkedin.com/company/ericsson
www.youtube.com/ericsson

 

 

MORE INFORMATION AT:

News Center

media.relations@ericsson.com
(+46 10 719 6996)

investor.relations@ericsson.com
(+46 10 719 00 00)

 

Ericsson is a world leader in communications technology and services with headquarters in Stockholm, Sweden. Our organization consists of more than 111,000 experts who provide customers in 180 countries with innovative solutions and services. Together we are building a more connected future where anyone and any industry is empowered to reach their full potential. Net sales in 2016 were SEK 222.6 billion (USD 24.5 billion). The Ericsson stock is listed on Nasdaq Stockholm and on NASDAQ in New York. Read more on www.ericsson.com.

 

 



Press release (PDF)



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: Ericsson North America, 100 Park Avenue, Suite 2705, New York 10036, U.S.A.
If you would like to unsubscribe and stop receiving these e-mails click here.

Gov UK: Press release:=?UTF-8?B?IFJlZ3VsYXRvcnMgZ2l2ZSBkZXNpZ24gYWNjZXB0YW5jZSB0byB0aGUgQVAxMDA=?==?UTF-8?B?MMKuIHBvd2VyIHN0YXRpb24gZGVzaWdu?=

Press release: Regulators give design acceptance to the AP1000® power station design
Read more

Press release: Statement from the Secretary of State for Wales in response to Snowdonia helicopter crash
Read more

Press release: Home Secretary statement: meeting with Communication Service Providers
Read more

Press release: Troika statement on South Sudan
Read more

Avance Gas Holding Ltd : Annual Report

Avance Gas Holding Ltd    

Published: 21:30 CEST 30-03-2017 /GlobeNewswire /Source: Avance Gas Holding Ltd / : AVANCE /ISIN: BMG067231032

Avance Gas Holding Ltd : Annual Report

Bermuda, 30 March 2017: Avance Gas (OSE: AVANCE) announces that the annual report for the financial year ended 31 December 2016 is published today.

 

A pdf-version of the annual report is attached and is also available on the company's website www.avancegas.com.

 

For further queries, please contact:

 

Peder C. G. Simonsen, CFO

Tel: +47 22 00 48 15 / Email: p.simonsen@avancegas.com

 

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.



Avance Gas - Annual report 2016



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: Avance Gas Holding Ltd, P.O.Box 370 Sentrum, Oslo 0102, Norge
If you would like to unsubscribe and stop receiving these e-mails click here.

Italeaf S.p.A.: Annual financial report 2016 - Consolidated and separated

Italeaf S.p.A.    

Published: 21:12 CEST 30-03-2017 /GlobeNewswire /Source: Italeaf S.p.A. / : ITAL /ISIN: SE0006143103

Italeaf S.p.A.: Annual financial report 2016 - Consolidated and separated

Italeaf S.p.A.
Annual financial report 2016



At its meeting today, the Company's Board of Director has approved the attached Annual Report 2016, conolidated and separated, for Italeaf S.p.A..

The report is only available online at www.italeaf.com.



Certified Adviser

Mangold Fondkommission AB is the Certified Adviser of Italeaf on NASDAQ OMX First North.

For further information please contact: 
Filippo Calisti

CFO - Italeaf S.p.A.

E-mail: calisti@italeaf.com

 

Mangold Fondkommission AB

Tel. +46 (0)8 5030 1550

info@mangold.se

 

Italeaf SpA, established in December 2010, is a holding company and a business accelerator for companies and startups in the areas of innovation and cleantech. Italeaf operates as a company builder, promoting the creation and development of industrial startups in the fields of cleantech, smart energy and technological innovation. Italeaf has headquarters and plants in Italy at Nera Montoro (Narni), Terni, Milano and Lecce; has international offices in London and Hong Kong and a research and development centre in the Hong Kong Science and Technology Park. The company controls TerniEnergia, listed on the STAR segment of the Italian Stock Exchange and active in the fields of renewable energy, energy efficiency and waste management, and Skyrobotic, in the business development and manufacture of civil and commercial drones in mini and micro classes for the professional market, Numanova, operating in the field of innovative metallurgy and additive manufacturing, Vitruviano LAB, a research center active in the R&D sector for special materials, green chemistry, digital transformation an cleantech, and Italeaf RE, a real estate company. 

 

 



ANNUAL REPORT 2016



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: Italeaf S.p.A., Strada dello Stabilimento, 1 - Nera Montoro, Narni (TR) 05035, Italy
If you would like to unsubscribe and stop receiving these e-mails click here.